A
_Abyssinia
Guest
A US biotech company said Thursday it will soon begin the first-ever European trials using human embryonic stem cells in an experimental treatment for people with a form of juvenile blindness.
The Massachusetts-based Advanced Cell Technology said the trials will involve 12 patients with Stargardt’s disease and will be based at Moorfields Eye Hospital in London, with more European sites planned for the future.
“This is the first time an embryonic stem cell trial has ever been approved anywhere else in the world,” said Bob Lanza, chief scientific officer at ACT and a longtime researcher in human embryonic stem cells.
The clearance to begin the European trials came from the UK Medicines and Healthcare products Regulatory Agency and the Gene Therapy Advisory Committee, ACT said.
Former president George W. Bush had blocked government funding for human embryonic stem cell research on new cell lines, citing religious grounds, a ban which President Barack Obama lifted in 2009.
google.com/hostednews/afp/article/ALeqM5j_uS6pqb3vSUPvOLEpwhYIlrcxqA?docId=CNG.ef5b01cbf496df64d0a1611c6d932c07.561
The Massachusetts-based Advanced Cell Technology said the trials will involve 12 patients with Stargardt’s disease and will be based at Moorfields Eye Hospital in London, with more European sites planned for the future.
“This is the first time an embryonic stem cell trial has ever been approved anywhere else in the world,” said Bob Lanza, chief scientific officer at ACT and a longtime researcher in human embryonic stem cells.
The clearance to begin the European trials came from the UK Medicines and Healthcare products Regulatory Agency and the Gene Therapy Advisory Committee, ACT said.
Former president George W. Bush had blocked government funding for human embryonic stem cell research on new cell lines, citing religious grounds, a ban which President Barack Obama lifted in 2009.
google.com/hostednews/afp/article/ALeqM5j_uS6pqb3vSUPvOLEpwhYIlrcxqA?docId=CNG.ef5b01cbf496df64d0a1611c6d932c07.561